Johnson & Johnson (JNJ)
Verdict history · JNJ
Every call Verdix has made on JNJ.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
See methodology for how verdicts are produced. Full track record →
Why the panel isn’t ready to call JNJ yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NYSE · Health Care / Pharmaceuticals & MedTech · 2026-08-15 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitHIGH confidence
Why
Johnson & Johnson checks every box for business quality — a wide moat, a confirmed post-Stelara growth thesis, and a first-ever $100B revenue milestone — but the panel is nearly unanimous that $260 is the wrong price to pay. Insider selling of $26M near the all-time high and a 30x P/E on mid-single-digit growth have five of six voices saying WAIT, with the debate centered on whether a 5-10% correction would be enough or whether only a deeper pullback to $200-$220 offers a genuine margin of safety.Level to watch
Key resistance 263.72+1.3% from 260.35
Next catalyst
Trigger to go Bullish: A decisive weekly close above $274.90 on expanding institutional volume, confirming the breakout is real and the insider selling was a false alarm.The panel's take
Verdict: WAIT · Conviction: HIGH · Last price: 260.35
This is the classic WAIT structure: every cautious voice agrees the business itself is high-quality — the moat, cash flows, and growth story are intact — but all object to the entry price. Five of seven voices are non-Bullish (technical scout WAIT, fundamental scout BALANCED, The Moat Compounder Bearish, The Intrinsic-Value Modeler Neutral, The Quality Rationalist Bearish, The Scuttlebutt Growth Investor Neutral, plus The Forensic Skeptic leaning Bearish), and every single objection is PRICE/TIMING-driven, not business-deterioration. The two explicit Bearish signals (The Moat Compounder, The Quality Rationalist) both say 'wonderful business, wrong price.' There is zero business-level dissent. Per Step B: BUY vs WAIT split (Bulls say buy now; the rest say great business, wrong price/timing) → synthesizes to WAIT, not BALANCED. The identifiable trigger is a pullback to $245-$252 or a breakout above $275 on expanding volume — both are concrete, measurable conditions.
Key levels
Key levels · JNJ
USD · as of 2026-08-15Analyst consensus target 260.35 USD · range 260.35–260.35
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Johnson & Johnson past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Moat CompounderValue/Quality/Moat🔴 BearishMed
Signal: A 30x trailing P/E on a business growing revenue at 4.8% offers no margin of safety, and the CEO sold $10.8M in stock near the all-time high while the company simultaneously raised guidance — insiders are voting with their feet. Conviction: Conviction is high because the overbought monthly RSI, thinning volume at elevated prices, and the shift from net cash to $28B net debt all independently argue the same thing: a wonderful business at the wrong price.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: A base-case DCF with 6% near-term revenue growth and 30% operating margins yields an estimated value of $248, and the stock at $260 is already pricing in the optimistic scenario with no cushion for execution risk. Conviction: Conviction is held back by the narrow gap between price and estimated value — a 5% downside to fair value is not a compelling short, but the asymmetry is negative until price drops meaningfully below intrinsic worth.
The Forensic SkepticContrarian/Forensic⚫ NeutralMed
Signal: Twenty-two insiders dumped $26M in stock over 90 days while 71% of analysts stamped Buy ratings and the stock traded within 5% of its all-time high — the gap between insider behavior and sell-side consensus is the widest signal on the tape. Conviction: Multiple independent flags — the quick ratio of 0.73, net debt of $28.3B, unresolved talc litigation, and monthly RSI at 72 on declining volume — reinforce each other, pushing conviction well past the neutral midpoint.
The GARP OperatorGrowth (GARP)⚫ NeutralMed
Signal: The PEG ratio sits at 2.86, nearly triple the growth rate, and the stock has run from $174 to $260 while volume thins at every new high — momentum chasers, not institutional accumulation, are driving the last leg. Conviction: Conviction is held back by the fact that the underlying business is genuinely excellent: a beat-and-raise quarter, confirmed post-Stelara thesis, and a first-ever $100B revenue milestone — if the stock corrects 10%, the whole picture flips.
The Quality RationalistMental Models/Quality🔴 BearishMed
Signal: The CEO liquidated $12.5M in shares days after guiding toward the first $100B revenue year, and a 30x P/E on a 4-6% grower mathematically guarantees mediocre long-run returns regardless of business quality. Conviction: The convergence of three separate frameworks — incentive-caused bias in analyst ratings, the inversion of what kills this investment (litigation, patent gaps, relevered balance sheet), and overbought technicals — leaves little room for a bullish outcome at this price.
The Scuttlebutt Growth InvestorGrowth/Management⚫ NeutralMed
Signal: The 15-point checklist scores 12 out of 15 with only one genuine caution flag, but the CEO and top legal officer both sold multimillion-dollar stakes within 48 hours of each other near the 52-week high — an integrity signal The Scuttlebutt Growth Investor would demand to resolve before committing new capital. Conviction: Conviction is tempered by the absence of any catalytic scuttlebutt insight that the market has missed: competitors respect the pipeline, customers are loyal, and the long-range outlook is genuinely positive, yet none of that changes the sticker price.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six archetypes agree JNJ is a high-quality business with a wide, durable moat — brands, patents, regulatory barriers, and hospital switching costs are intact.
- Every voice on the panel acknowledges that the Q2 beat-and-raise and the first-ever $100B revenue guidance validate the post-Stelara thesis.
- No one disputes that the current price of $260 is rich: the P/E multiple has expanded from ~18x at the 2023 lows to 30x trailing without a proportionate improvement in the growth rate.
- The $26M in insider selling over 90 days, led by the CEO and Chief Legal Officer near the all-time high, is flagged by every archetype as a signal that demands explanation, even if some frame it as caution and others as a red flag.
The real debate
- The Moat Compounder and The Quality Rationalist see a 30x P/E on a mid-single-digit grower as structurally overvalued and warrant a pullback to $200-$220 for a margin of safety, while The Intrinsic-Value Modeler's base case puts fair value at $248 — only 5% below the current price — making the overvaluation less severe and the call more sensitive to growth assumptions.
- The Forensic Skeptic treats the insider selling as the single most actionable data point, arguing it negates the bullish consensus, whereas The Scuttlebutt Growth Investor sees it as a resolvable yellow flag that could be explained by a 10b5-1 plan and does not disqualify a company that passes 12 of 15 checklist items.
- The GARP Operator and The Moat Compounder both want a pullback but differ on where: the former's PEG framework points to $245-$250 as the zone where the math improves, while the latter demands $200-$220 for a true margin of safety — a gap that hinges on how much premium JNJ's moat genuinely deserves.
The question it comes down to: Does the insider selling signal that JNJ is near peak valuation and due for a correction, or is it routine portfolio management that will look irrelevant once earnings growth compresses the multiple from 30x toward fair value over the next 12-18 months?
The bottom line
- Trigger to go Bullish: A decisive weekly close above $274.90 on expanding institutional volume, confirming the breakout is real and the insider selling was a false alarm.
- Price level for a better entry: A pullback to the $245-$252 zone, where the weekly EMA20 and former resistance-turned-support converge, would compress the forward P/E toward 20-21x and satisfy the GARP and fair-value frameworks.
- Risk to monitor: A weekly close below $224.68 (the weekly EMA50) would break the intermediate uptrend and flip the panel's verdict from WAIT to SELL regardless of business quality.
- Insider-trading catalyst: The first Form 4 filing showing open-market insider buying — not option exercise or grant — would neutralize the panel's single most cited objection and could shift at least two cautious voices toward Bullish.
- Litigation overhang: A definitive talc or opioid settlement that caps the liability at a known dollar figure removes the largest unquantified risk on the balance sheet and would allow the DCF models to tighten their downside scenarios.
contact@verdixhq.com · Published 2026-08-15 · Prices as of 2026-08-15 · Time horizon: 3–12 months · No direct position held in JNJ · JNJ verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated